Navigation Links
Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
Date:3/18/2009

BALTIMORE, March 18 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, reports its financial results for the third fiscal quarter ended January 31, 2009. Full details of the Company's financial results are available in the Company's Form 10-Q at www.championsbiotechnology.com.

Total revenues for the third quarter of fiscal 2009 increased to $1,052,175, compared to $624,940 for the same period in 2008. The Company derived its revenues from its Personalized Oncology and its Preclinical eValuation businesses.

Total operating expenses for the third fiscal quarter of 2009 were $1,696,457 compared to $319,998 for the same period of last year. Third quarter 2009 operating expenses included the following:

Research and development expenses were $435,274, compared to $0.00 for the comparable prior period in fiscal 2008. The increase of $435,274 was primarily related to the Company's effort to build its preclinical platform and drug pipeline and develop its drug, SG410. In addition, the Company incurred expenses related to its business development activities and personnel.

The costs of personalized oncology and preclinical eValuation services were $898,777 for the quarter ended January 31, 2009, as compared to $201,222 in the quarter ended January 31, 2008. The increase in personalized oncology costs relates mainly to the overall growth in the business and a $250,000 payment to fund the cost of a Personalized Vaccine(TM) program the Company entered into during the current quarter. The Personalized Vaccine program is structured such that the cost to establish the program is incurred primarily in the third and fourth quarter; if the program successfully continues i
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
2. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
3. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
4. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
5. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
6. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
7. Biotechnology Value Fund Urges Stockholders to Remove and Replace Current Board of Avigen, Inc. in an Effort to Protect and Maximize Stockholder Value
8. Canadian Government Announces Funding for Leading Biotechnology Firms Project
9. InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies
10. FDA Provides A Positive Review of InNexus Biotechnology Development Plan for Lead Product
11. PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprovas Enantiomers of DOTAP Chloride in Immunotherapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Flagship Biosciences LLC, a leading provider of ... medical device industries, has announced a laboratory and office ... consolidated its histology and tissue analysis operations from separate ... north of Denver. The new addresses are: , ... 100, Westminster, CO 80021 , Tissue Image Analysis Lab, ...
(Date:8/27/2014)... Beach County, Florida (PRWEB) August 27, 2014 ... Company Inc. (SCI) is announcing the creation of ... priority is to take the SCI’s philosophy of ... the company’s research and development actions are based ... , This new Scientific Advisory Board provides a ...
(Date:8/27/2014)... NJ (PRWEB) August 27, 2014 WriteResult, ... services – has once again shown superiority when it ... sponsor by completing the ePRO portion of their most ... The Japan-based pharma chose WriteResult’s digital writing platform ... trials – the first to complete drew data from ...
(Date:8/26/2014)... LONDON , Aug. 26, 2014 An ... gene structures of all Mers CoV virus ... Replikin structures back to 2012.  This conservation and sharing ... of a Synthetic Mers CoV Blocker-Vaccine™ candidate, as it did ... Shrimp vaccine, both of which have been found to ...
Breaking Biology Technology:Flagship Biosciences Announces Relocation and Expansion 2New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2
... /Xinhua-PRNewswire-FirstCall/ -- American Oriental,Bioengineering, Inc. (NYSE: AOB ... quarter 2008 financial results on Monday, November 10, ... hold a conference call at 8:00 am ET ... 2008 results. Listeners may access the,call by dialing ...
... 30 /PRNewswire-FirstCall/,-- Oridion Systems Ltd. (SWX: ORIDN) ... Foundation Health Plan, Inc., America,s largest,non-profit health ... in the world. The agreement is for ... sampling consumables (FilterLine(R))., With this agreement, ...
... ... Guidance of $0.90 - $1.10 for 2009 and $1.50 - $1.70 ... for 2010, PITTSBURGH, Oct. 30 ... months ended,Sept. 30, 2008., Financial Highlights, -- Adjusted diluted EPS of $0.23 and $0.52 ...
Cached Biology Technology:Oridion Signs Agreement With Major US Health Plan Provider for Microstream(R) Capnography 2Oridion Signs Agreement With Major US Health Plan Provider for Microstream(R) Capnography 3Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 2Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 3Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 4Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 5Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 6Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 7Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 8Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 9Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 10Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 11Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 12Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 13Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 14
(Date:8/27/2014)... of consumers are willing to pay a premium for ... they,re getting what the label claims is another matter. ... a new way to make sure farms are labelling ... Journal of Agricultural and Food Chemistry , could ... Bavarian Health and Food Safety Authority and the Wuerzburg ...
(Date:8/27/2014)... studies have shown that excessive iron is ... disease. Previous studies from Chunyan Guo and ... have shown that baicalin prevented iron accumulation ... transporter 1 expression, and increased ferroportin 1 ... Parkinson,s disease rats. However, the relationship between ...
(Date:8/27/2014)... are greedy bird-brains, University of Warwick research finds ... they make risky decisions, new research has shown. , ... of Warwick,s Department of Psychology, conducted tests that found ... likely to gamble for high-value than low-value rewards. , ... that the test results show the important role that ...
Breaking Biology News(10 mins):Gamblers are greedy bird-brains, University of Warwick research finds 2
... and the U.S.A., the scientists have shown how cutting-edge ... of active proteins in cell organelles at a particular ... use proteins. The work is published in the journal ... cities. They contain all the necessary parts that allow ...
... the use of liquid crystalline polymers (LCP) as a ... sought-after lab-on-a-chip technology. , University of Alberta researchers, collaborating ... Phillips Research Laboratories in the Netherlands, have shown that ... glass backing, can be fabricated and patterned on a ...
... of dengue fever wax and wane over a period ... why. With the incidence and range of the potentially ... these epidemics has never been more important. , A ... suggests that a brief period of cross-immunity conferred by ...
Cached Biology News:A catalogue of proteins 2Polymers show promise for lab-on-a-chip technology 2UGA study explains peaks and troughs of dengue epidemics 2UGA study explains peaks and troughs of dengue epidemics 3
Request Info...
Request Info...
Detect and measure levels of mouse IgG2b antibody isotypes quickly and easily....
Detect and measure levels of mouse IgG3 antibody isotypes quickly and easily....
Biology Products: